ACLX News and Press, Arcellx Inc. From 11/13/23

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights PR Newswire -- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Arcellx Inc. (ACLX) is expected to report $-0.56 for Q3 2023

2023-11-02 12:44:44 ET More on Arcellx, Gilead, etc. Gilead Sciences Stock Is Cheap, With Broad Pipeline Gilead Sciences: Does The Stocks Reward Outweigh The Risk Gilead Sciences: A Healthy Buy With Solid Dividend Eli Lilly, Gilead favorites at BofA ahead of ...

2023-11-02 10:01:01 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition PR Newswire -- Abstract released today is from a June 2, 2023 data cut -- -- Median duration of re...

Arcellx to Participate in Two Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for p...

2023-10-23 02:50:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms. Immunotherapie...

2023-09-06 10:54:25 ET Summary Arcellx is a biotech firm developing advanced cell therapies for diseases like cancer, with a focus on their CART-ddBCMA program for multiple myeloma. Recent positive FDA developments have lifted the clinical hold on Arcellx's T-cell therapy for mult...

2023-08-21 20:10:21 ET Summary Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal would translate to quarterly net sales of near...